Molecular Evidence Supporting MEK Inhibitor Therapy in NF1 Pseudarthrosis
Journal of Bone and Joint Surgery · 2025
DOI: 10.2106/jbjs.24.01007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Bone and Joint Surgery, 2025. Verfasst von Nandina Paria und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Research, Scottish Rite for Children, Dallas, Texas. Hauptthemen laut MEDLINE: Pseudarthrosis, Neurofibromatosis 1, Pyridones, Pyrimidinones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Neurofibromatosis type 1 (NF1) is a genetic condition predisposing children to fracture pseudarthroses. MEK inhibitors are U.S. Food and Drug Administration–approved or are under study for the treatment of malignant pathologies associated with NF1. However, their potential to treat pseudarthrosis is largely unknown.
Methods
Primary cells cultured from control bone or fracture pseudarthroses from children with NF1 were treated with vehicle or with the MEK inhibitors trametinib or selumetinib. Gene expression was evaluated with use of transcriptome sequencing (RNAseq), and the activation of the downstream signaling pathway was evaluated with use of western blotting. Results were replicated in an independent cohort of patient fracture pseudarthrosis-derived primary cells.
Results
Pseudarthrosis samples were reproducibly associated with the reduced expression of gene signatures implicated in osteoblast differentiation, skeletal development, and the formation of the extracellular matrix. The expression of these gene signatures was significantly rescued following treatment with MEK inhibitors and concomitant reduced MEK/ERK (MAPK) pathway activation.
Conclusions
Our study identified molecular signatures associated with fracture pseudarthrosis that were rescued with MEK inhibitor treatment. Clinical Relevance: MEK inhibitors may promote the healing of fracture pseudarthroses in children with NF1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Translational Research, Scottish Rite for Children, Dallas, Texas.
- Department of Orthopedics, Scottish Rite for Children, Dallas, Texas.
- Department of Orthopaedic Surgery, UT Southwestern Medical Center, Dallas, Texas.
- McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, Texas.
- Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas.
- Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas.
ORCID-Profile: Ila Oxendine, David Podeszwa, Meghan Wassell, Carol A Wise, Jonathan J Rios
Zitieren
APA
Paria, N., Oxendine, I., Podeszwa, D., Wassell, M., Cornelia, R., Wise, C. A., & Rios, J. J. (2025). Molecular Evidence Supporting MEK Inhibitor Therapy in NF1 Pseudarthrosis. Journal of Bone and Joint Surgery. https://doi.org/10.2106/jbjs.24.01007
Vancouver
Paria N, Oxendine I, Podeszwa D, Wassell M, Cornelia R, Wise CA, et al. Molecular Evidence Supporting MEK Inhibitor Therapy in NF1 Pseudarthrosis. Journal of Bone and Joint Surgery. 2025. doi:10.2106/jbjs.24.01007
BibTeX
@article{Paria2025,
author = {Paria, Nandina and Oxendine, Ila and Podeszwa, David and Wassell, Meghan and Cornelia, Reuel and Wise, Carol A and Rios, Jonathan J},
title = {Molecular Evidence Supporting MEK Inhibitor Therapy in NF1 Pseudarthrosis},
journal = {Journal of Bone and Joint Surgery},
year = {2025},
doi = {10.2106/jbjs.24.01007}
}
EUVIMED